Humana shares surge 6.72% after-hours as Barclays raises price target to $315 and institutional investors boost holdings.

Humana surged 6.72% in after-hours trading following two key developments: (1) the company’s Medicare Advantage Plan secured prior authorization for Lifeward’s ReWalk 7 exoskeleton, marking a second major insurer (after UnitedHealthcare) to expand access to the technology, enhancing Humana’s reputation for innovative care solutions, and (2) Barclays raised its price target for Humana to $315 from $275, citing improved valuation metrics and growth prospects. The Lifeward approval underscores Humana’s leadership in advancing reimbursement pathways for cutting-edge medical devices, while the analyst upgrade reinforces confidence in its strategic positioning amid evolving healthcare trends. Both events directly contributed to the post-market rally, aligning with the stock’s upward trajectory.